NIH RFA · RMOD · UG3, UH3
RFA-RM-27-013: Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
The overarching goal of this notice of funding opportunity (NOFO) and its companion opportunities is to establish the Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) Program to support development of innovative, reliable, cost-effective, and sustainable multimodal AI-based clinical decision support (CDS) tools. PRIMED-AI CDS tools are based on the integration of clinical imaging with other types of multimodal health data to enhance care for patients with a wide range of health conditions. The PRIMED-AI Program seeks to catalyze the adoption of AI-based CDS tools into clinical workflows to enable novel personalized medicine strategies that address significant…
- NOFO number
- RFA-RM-27-013
- Type
- RFA
- Activity code
- UG3UH3
- Primary institute
- RMOD
- Clinical trials
- Optional
- Posted
- Jun 30, 2026
- Opens
- Sep 19, 2026
- Expires
- Oct 20, 2026
RFA-RM-27-013 due dates
1 application due date remains before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| New | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| October 19, 2026 | Not Applicable | Not Applicable | March 2027 | May 2027 | July 2027 |
Funded projects
NIH RePORTER lists no awards under RFA-RM-27-013 in FY2022–FY2026, and it is a new NOFO rather than a reissue. Awards usually appear a few months after the first review cycle.
Participating institutes
3 NIH institutes and offices take applications under RFA-RM-27-013. Contact the program officer at the institute that fits your research before applying.
- RMOD
- NOFO
- none
Related notices
NIH lists no related notices for RFA-RM-27-013 yet.
Award terms
- Application types allowed
- New The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Applicants should request a budget appropriate for the proposed scope of work, not to exceed 450,000 in direct costs per year for UG3 and 1,000,000 in direct costs for UH3 phases.
- Project period
- The total project period for a UG3/UH3 award may not exceed 5 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The NIH Common Fund intends to commit funds for approximately 6-8 UG3/UH3 awards. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Companion NOFOs: RFA-RM-27-011, RFA-RM-27-012, RFA-RM-27-014, RFA-RM-27-015.
Other open NOFOs for UG3, UH3
- RFA-RM-27-012PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)RMOD · next due Oct 19, 2026
- RFA-RM-27-007Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)RMOD · next due Nov 23, 2026
- PAR-27-015Community-Based Participatory Research to Advance Data and Practice Transformation (ADAPT) for Optimizing Oral Health for All (UG3/UH3 Clinical Trial Optional)NIDCR · next due Oct 16, 2026
- PAR-25-296Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)NCATS · next due Oct 19, 2026
- PAR-25-226Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)NIA · next due Oct 19, 2026
- PAR-25-052NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)NINDS · next due Oct 19, 2026
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.